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and prognosis when patients with WCH were compared with a normotensive population (9) . MH was shown to be associated with an increased risk for CV events in multiple populations in Europe and Asia (5, 7, (10) (11) (12) (13) . However, these studies included few subjects of African descent, the racial/ethnic group with the greatest burdens of hypertension and hypertensive target organ damage.
Furthermore, CV risks associated with WCH and MH differed depending on the presence or absence of antihypertensive treatment (5, 6) . Among the treated population, MH is proposed to represent inadequately treated hypertension, whereas patients with Tientcheu et al. 
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WCH are at risk for overtreatment because of persistently elevated office BP (14) . However, the prognostic significance of treated and untreated MH and WCH has not been evaluated in the general population in the United States.
Accordingly, we determined the extent of target organ complications and CV prognosis associated with MH and WCH in participants of the DHS (Dallas Heart Study), a multiethnic, probability-based population sample of Dallas County, Texas, adults. The presence or absence of WCH and MH was determined by home and clinic BP measurements obtained in the same subjects using the same instruments and protocols. We also determined CV outcomes on the basis of the presence or absence of antihypertensive treatment prescribed to each participant.
METHODS STUDY POPULATION.
The DHS is a multiethnic, probability-based population sample of Dallas County residents ages 18 to 65 years, established in 2000, as previously described (15) . This study was designed to oversample African Americans, with a resultant cohort that includes 54% African Americans and 49% women. The median age of our participants was 43 years. All participants in the DHS provided written informed consent, and the Uni- CV Outcomes in Masked Hypertension the Netherlands), as previously described (20) . Mortality data were queried from the National Death The sample-weighted prevalence rates of masked hypertension (MH) and white-coat hypertension (WCH) were 17.8% and 3.3%, respectively. NT ¼ normotension; SBP ¼ systolic blood pressure; SH ¼ sustained hypertension.
Tientcheu et al. with NT after adjustment for age, sex, race, diabetes, self-reported hypertension, home systolic blood pressure, estimated glomerular filtration rate, high-sensitivity C-reactive protein, and allometric height. ‡p < 0.05 compared with NT after adjustment for age, sex, race, diabetes, self-report hypertension, home systolic blood pressure, estimated glomerular filtration rate, high sensitivity C-reactive protein, and allometric height.
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RESULTS
Baseline characteristics of all participants are shown in (1.37 AE 0.72) was also not different from that in the Tientcheu et al.
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N O V E M B E R 1 7 / 2 4 , 2 0 1 5 : 2 1 5 9 -6 9 MH group (1.33 AE 0.74; p ¼ NS) but was higher than in the treated NT group (p < 0.01) ( Table 1) .
ASSOCIATIONS BETWEEN WCH AND MH AND CV
OUTCOMES. Over a median follow-up period of 9.4 years (IQR: 9.0 to 9.8 years), 47 CV deaths and 194 composite CV events were recorded. Hazard ratios for composite CV events in participants with WCH, MH, and SH are presented in Table 2 and Online   Table 3 , and Kaplan-Meier survival curves are presented in Figure 3 . 
DISCUSSION
The major findings of our study are 3-fold. First, MH was common in our cohort, occurring in 18% of participants overall and in 14% of those not receiving antihypertensive treatment, comprising >50% of the prevalent hypertension cases in the Development in Young Adults) study, the investigators reported that the prevalence of MH was only 2.1% to 4.4%, whereas the prevalence of WCH was 3.3% to 3.9% (23) . However, participants in the CARDIA study were more than a decade younger than our cohort, and the sample size was limited to a subset of 281 subjects. In contrast, a recently published report from the JHS (Jackson Heart Study), which is limited to African Americans, reported 25.9% prevalence of MH and 7.5% prevalence of WCH (24) . The difference in ethnic composition and the use of 24-h ambulatory BP monitoring in the JHS may explain the difference in the study results. Nevertheless, our data are quite consistent with those from a large international registry of ambulatory BP monitoring, in which the prevalence of MH among subjects 40 to 50 years of age was between 12% and 28%, and the reported prevalence of WCH was between 3.6% and 4.1% (25) .
Previous studies have demonstrated inconsistent results with regard to CV outcomes associated with WCH. Results from a published meta-analysis conducted by Pierdomenico and Cuccurullo (9) showed that the CV prognosis of patients with WCH was not significantly different from that of those with NT among an untreated population.
Similarly, results of analyses from IDACO (International Database on Ambulatory Blood Pressure in
Relation to Cardiovascular Outcomes) (6) and SystEur (Systolic Hypertension in Europe) (26) showed that WCH was not associated with an increase in CV events in the treated group. In contrast, results from a meta-analysis by Stergiou et al. (5) showed increased risk for CV events in patients with untreated WCH. Explanations underlying the WCH is proposed to result from stress-induced activation of the sympathetic nervous system during encounters with health care providers (27) , whereas MH is potentially induced by mental stress at home, excessive consumption of alcohol, caffeine consumption, and cigarette smoking, among other potential confounders (14) . Furthermore, MH while on drug treatment is proposed to reflect a shift of phenotype from SH to inadequately treated hypertension (14) . In contrast, WCH is thought to lead to overtreatment of hypertension because of persistently elevated clinic BP (14) . However, in our study, the number of antihypertensive drugs prescribed in the WCH group was similar to that in the group with controlled hypertension, both at home and in the clinic. Because average home BP in the treated WCH group (Online Table 2 ) was similar to the treated NT group, our study did not suggest overtreatment of hypertension in the WCH group. Similarly, the number of antihypertensive drugs prescribed to patients with MH was not different from the SH group, whereas both clinic and home BPs were lower in the MH than in the SH group (Online Kaplan-Meier curves for the cumulative incidence of composite cardiovascular events among the normotension, white-coat hypertension, masked hypertension, and sustained hypertension groups. BP ¼ blood pressure; HTN ¼ hypertension. Last, statistical analysis in this study was not adjusted for multiple testing between WCH, MH, and SH versus control groups. However, our analysis was performed on the basis of a separate, pre-stated hypothesis suggested by prior published evidence.
Because we did not stray into non-hypothesis-driven exploration, we believe this is an acceptable approach. 
CONCLUSIONS
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